IN8bio Inc
INAB
NASDAQ
Biotechnology
$1.10
USD
-0.08 (-6.78%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $11.63M
Volume 56.0K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-18.98M
TTM
+30.8%
YoY
Operating Cash Flow
$-14.54M
TTM
+24.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 2.7 | 2.7 | 1.9 | 2.4 | 2.7 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 5.7 | 5.2 | 4.0 | 5.0 | 5.3 |
Operating Income | -5.7 | -5.2 | -4.0 | -5.0 | -5.3 |
EBITDA | -5.4 | -4.9 | -3.7 | -4.8 | -5.0 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 |
Income Before Income Taxes | -5.6 | -5.1 | -3.9 | -4.9 | -5.1 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -5.6 | -5.1 | -3.9 | -4.9 | -5.1 |
Consolidated Net Income / Loss | -5.6 | -5.1 | -3.9 | -4.9 | -5.1 |
Net Income Attributable to Common Shareholders | -5.6 | -5.1 | -3.9 | -4.9 | -5.1 |
Basic EPS | -$2.16 | -$1.24 | -$0.85 | -$0.79 | -$0.26 |
Diluted EPS | -$2.16 | -$1.24 | -$0.85 | -$0.79 | -$0.26 |
Basic Shares Outstanding | 2.6M | 4.1M | 4.5M | 6.3M | 19.5M |
Diluted Shares Outstanding | 2.6M | 4.1M | 4.5M | 6.3M | 19.5M |